

INVESTOR ANNOUNCEMENT 18 OCTOBER 2023

NATURAL MEDTECH APPOINTS FORMER PFIZER EXECUTIVE MARIO GATTINO (GAICD) TO THE BOARD OF DIRECTORS

Natural MedTech Pty Ltd (“NMT”) is pleased to announce the appointment of Mario Gattino as a Non-Executive Director, effective immediately.

Mario has over 30 years’ experience working in the global pharmaceutical and biotechnology sector across research and development, operations, process improvement, corporate strategy and stakeholder management. He spent 20 years at Pfizer, with four years as Country CEO (Hungary) & Regional Managing Director of Distribution for the Central-Eastern European Region and three years as COO of Northern Europe. Additionally, he held senior executive roles at Respire, Ikaria ANZ and MG Squared Ventures. During his career, he led business units with over \$1.5 billion in revenue.

During Mario’s successful career, he has focused on driving growth, product commercialization and integrating business transformations across North America, Europe, Asia Pacific and Latin America. Mario has won multiple industry awards including the prestigious Batthyány-Strattmann László Award in Hungary for his contribution in attracting research and development (First non-Hungarian to be awarded this honour).

Mario completed a Senior Leadership Executive Program at Harvard Business School, an Executive MBA at the University of New South Wales, a Graduate Diploma in Management at the University of New South Wales and a Bachelor of Applied Sciences at La Trobe University.

Natural MedTech’s Chair, Peter Schubert said:

“It is with great pleasure that we welcome Mario to the board of Natural MedTech. Mario has substantial experience in the global pharmaceutical industry and we are thrilled to attract someone of his calibre to the team. Mario’s deep industry expertise and broad network will be invaluable as we advance our goal of becoming a global producer of psychedelic molecules. The Board and the entire team look forward to working with Mario during this exciting stage of NMT’s growth.”

Commenting on his appointment, Mario Gattino said:

“I am honoured and very excited to be joining the board of Natural MedTech at this time. My fellow board members are an impressive collection of successful and talented leaders who have done an outstanding job in evolving the potential of Natural MedTech’s portfolio to such a compelling inflection point with near-term catalysts set to propel its growth. Having worked across just about every therapeutic area over my time at Pfizer and beyond, it is rare and highly stimulating to be involved with the promise of psychedelic treatments and in particular psilocybin. This at a time when opinion leaders and regulatory authorities globally are advocating and expediting their development and access for a range of debilitating conditions. I feel privileged to contribute to the exciting journey that Natural MedTech is embarking on, in impacting positively the lives of so many people.”

If you have any questions, please don’t hesitate to contact:

Luke McFarlane, Managing Director
luke.mcfarlane@naturalmedtech.com

+61 414 194 067